News
VSTM
9.65
-0.92%
-0.09
Weekly Report: what happened at VSTM last week (0415-0419)?
Weekly Report · 1d ago
Verastem Oncology Names John Hayslip as Chief Medical Officer
Verastem Oncology named John Hayslip as chief medical officer. He succeeds Louis Denis, who recently left the biopharmaceutical company. Hays Lip has more than 25 years of oncology and research and development experience. He will lead development for Verastem's cancer treatment.
Dow Jones · 5d ago
VERASTEM ONCOLOGY ANNOUNCES APPOINTMENT OF JOHN HAYSLIP, M.D., TO CHIEF MEDICAL OFFICER
Reuters · 5d ago
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
TipRanks · 04/16 10:00
Weekly Report: what happened at VSTM last week (0408-0412)?
Weekly Report · 04/15 11:43
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
TipRanks · 04/12 11:00
Verastem Releases Updated Corporate Presentation for Investors
TipRanks · 04/09 21:22
Weekly Report: what happened at VSTM last week (0401-0405)?
Weekly Report · 04/08 11:49
VERASTEM ONCOLOGY ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/04 11:30
Weekly Report: what happened at VSTM last week (0325-0329)?
Weekly Report · 04/01 11:46
Catalyst Watch: Tesla deliveries, Disney board vote, DJT drama and Fortinet event
Volatility watch - Options trading volume is elevated on Trump Media & Technology (DJT) Key data reports due to arrive this week include updates on Tesla deliveries, Disney board vote, and Solventum spin-off. Fortinet will hold its four-day Accelerate 2024 event in New York.
Seeking Alpha · 03/28 19:00
Verastem’s Strategic Advancements and Financial Stability Underscore Buy Rating
TipRanks · 03/27 07:15
Weekly Report: what happened at VSTM last week (0318-0322)?
Weekly Report · 03/25 11:49
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 03/24 12:01
Verastem: Statement of changes in beneficial ownership of securities
Press release · 03/21 00:08
Verastem Price Target Maintained With a $17.50/Share by HC Wainwright & Co.
Dow Jones · 03/19 10:47
Verastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term Losses
TipRanks · 03/19 10:18
Weekly Report: what happened at VSTM last week (0311-0315)?
Weekly Report · 03/18 11:47
Analysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)
Verastem (VSTM) and Akebia Therapeutics (AKBA) have been recommended by 2 analysts. BTIG analyst Justin Zelin reiterated a Buy rating on Verastem yesterday and set a price target of $27.00. In a report released yesterday, Julian Harrison from BTIG maintained a buy rating on Akebia.
TipRanks · 03/16 16:30
Verastem Inc. at a Crossroads: Navigating the Perilous Terrain of Patent Ownership and IP Rights
TipRanks · 03/16 06:02
More
Webull provides a variety of real-time VSTM stock news. You can receive the latest news about Verastem through multiple platforms. This information may help you make smarter investment decisions.
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).